TL;DR: Retatrutide (research code LY3437943), informally nicknamed “GLP-3”, is a single synthetic peptide that activates three metabolic receptors at once — GIP, GLP-1, and glucagon. That third target, the glucagon receptor, is what separates it from every incretin compound before it. The design logic is that the two incretin arms cancel out glucagon's blood-sugar downside, leaving its energy-expenditure effect intact. Published Phase 2 data show the largest body-weight reductions recorded in the class, though why the effect is that large remains an open question. Retatrutide is investigational and supplied for research use only.
What Is GLP-3?
“GLP-3” (also written GLP3) is not a hormone, a receptor, or a drug class. It is the informal nickname that forums, research vendors and a growing share of news coverage use for retatrutide — development code LY3437943, the single peptide described throughout this article, which activates the GIP, GLP-1 and glucagon receptors together. The logic of the nickname is arithmetic: semaglutide acts on one incretin receptor, tirzepatide on two, retatrutide on three, so “GLP-3” became shorthand for the third generation of the class. Eli Lilly, which developed the compound, calls the label scientifically inaccurate, and it is right to. The gut produces two glucagon-like peptides, GLP-1 and GLP-2; there is no GLP-3 in human physiology and no GLP-3 receptor for a molecule to bind.
In practice the term appears on research-vendor listings as “GLP-3”, “GLP-3 RT”, “RTA” or “Triple G”, alongside the older abbreviation “reta”. All of them refer to the same molecule. A listing that describes a “GLP-3 receptor” product is making a naming error, not selling something different. Helix North lists the compound under its full name; see retatrutide (GLP-3) in Canada for vial sizes, testing and shipping.
What "Triple Agonist" Actually Means
An agonist is a molecule that binds a receptor and switches it on, imitating whatever hormone normally does the job. A triple agonist is one engineered molecule that performs this trick at three different receptors simultaneously — not three compounds administered together, but a single peptide chain whose structure is close enough to three separate hormones that all three receptors accept it.
That distinction matters more than it first appears. Combining three separate drugs means three pharmacokinetic profiles, three absorption curves, and three sets of interactions to control. A single molecule hitting three targets delivers all three signals with one half-life and one concentration curve. The engineering problem is making one sequence that fits three different receptor pockets well enough to activate each, which is why the class took so long to arrive.
The Three Receptors, One at a Time
Each of retatrutide's three targets contributes something distinct, and the compound's behaviour only makes sense once they are separated out.
| Receptor | Natural role | Contribution in a triple agonist |
|---|---|---|
| GLP-1 | Incretin hormone; boosts glucose-dependent insulin release, slows gastric emptying, signals satiety in the brain | Appetite suppression and glycemic control — the arm shared with semaglutide |
| GIP | Incretin hormone; amplifies insulin response and influences fat-tissue handling of nutrients | Added insulin sensitivity and, in published work, improved tolerability alongside GLP-1 |
| Glucagon | Counter-regulatory hormone; mobilizes liver glucose and raises energy expenditure | Increased energy expenditure and hepatic fat mobilization — the arm unique to retatrutide |
Semaglutide engages the first row only. Tirzepatide engages the first two. Retatrutide engages all three, which is the entire basis for treating it as a separate category rather than an incremental improvement. Our GLP-1 receptor agonist primer covers the incretin arms in more depth.
Why Add Glucagon to the Mix?
Glucagon is best known as insulin's opposite number. When blood sugar drops, glucagon tells the liver to release stored glucose. Taken at face value, adding a glucagon signal to a metabolic compound sounds counterproductive — it is the hormone that raises blood sugar.
But glucagon does something else as well: it raises energy expenditure and drives fat mobilization from the liver. That second property is what makes it interesting, and the problem has always been that it comes bundled with the first.
Combined with strong GLP-1 and GIP signalling, the arithmetic changes. The incretin arms boost glucose-dependent insulin release and stabilize glycemic control, which offsets glucagon's blood-sugar-raising tendency. What is left, at least in principle, is glucagon's energy-expenditure effect without its glycemic penalty.
Think of it as adding a third lever to a machine that already has two — the existing levers are there to cancel the new lever's downside, leaving only the part worth having.
Whether that cancellation is complete across the whole dose range is exactly what the trials are characterizing. Published Phase 2 data record small, dose-dependent heart-rate increases attributed to the glucagon arm, and glucose-parameter movement at higher doses even as overall control improved. Our retatrutide side-effects article works through those findings in detail.
Retatrutide vs Tirzepatide at the Receptor Level
Because tirzepatide is the closest comparator, the receptor-level difference is worth stating precisely: retatrutide is tirzepatide's two receptors plus one more. Both compounds agonize GIP and GLP-1. Retatrutide adds glucagon.
This is not a case of one compound being a stronger version of the other. The shared incretin arms behave broadly similarly; the divergence is a genuinely additional signalling pathway with its own downstream consequences — energy expenditure, hepatic fat handling, and the cardiovascular and glycemic considerations that come with it. A compound with a different mechanism is not simply a compound with more of the same mechanism, which is why the two are studied separately rather than as dose equivalents. The retatrutide vs tirzepatide comparison sets the published data side by side.
GLP-3 vs GLP-1: What the Nickname Gets Right and Wrong
What it gets right is the direction of travel. A GLP-1 agonist such as semaglutide engages one receptor; the compound people call GLP-3 engages three, and the published Phase 2 trial recorded larger group-mean weight reductions than earlier single-agonist trials had reported at a comparable timepoint. The nickname also correctly signals that retatrutide is not simply a stronger GLP-1 drug — the glucagon arm is a different pathway with its own consequences for energy expenditure and heart rate.
What it gets wrong is the implied lineage. GLP-2 is a real gut hormone involved in intestinal repair, not a step between GLP-1 drugs and retatrutide, and “GLP-3” does not exist as a hormone at all. Nor is retatrutide an approved medicine anywhere: as of September 2026 it remains in Phase 3 trials, so “GLP-3” names an investigational compound rather than a prescription option. Our retatrutide vs semaglutide comparison sets the single-agonist and triple-agonist data side by side.
Appetite Signalling and the "Food Noise" Question
One of the most common questions about this class concerns "food noise" — the colloquial term for intrusive, repetitive thoughts about eating. It is worth being precise here, because the honest answer is more limited than most discussion suggests.
Food noise is not a measured endpoint in the published retatrutide trials. What the literature does establish is that GLP-1 receptor agonism acts on appetite-regulating regions of the brain, and that trial participants across the incretin class report reduced appetite. Retatrutide carries the GLP-1 arm, so the mechanistic basis is present. But moving from "GLP-1 agonism reduces reported appetite" to "retatrutide reduces food noise" is extrapolation, not a trial finding. The distinction between what was measured and what is inferred is one worth preserving throughout this topic.
What the Phase 2 Trial Showed
The Phase 2 trial published in The New England Journal of Medicine (Jastreboff et al., 2023) followed adults with obesity for 48 weeks across several dose arms. It reported substantial body-weight reductions at every dose studied, with the 12 mg arm reaching a mean reduction of roughly 24 percent — larger than any prior incretin-class study had recorded at a comparable timepoint.
Two caveats belong alongside that number. It is a Phase 2 result, meaning a smaller population than the Phase 3 programme now underway. And it is a group mean, not an individual outcome. Our summary of the weight-loss research unpacks the dose-response curve, and the FDA approval status article covers where the Phase 3 TRIUMPH programme currently stands.
Why the Effect May Exceed the Sum of Its Parts
The most interesting open question in this area is why the effect size is as large as it is. Two explanations compete, and they are not mutually exclusive.
- The additive account. Energy expenditure rises through the glucagon arm while appetite falls through the incretin arms. Two independent mechanisms pushing in the same direction produce a larger combined effect. Simple, and probably at least partly true.
- The synergy account. Some published work suggests that activating several incretin-family receptors at once produces downstream signalling effects greater than each pathway would generate alone — receptor cross-talk, rather than simple addition. If correct, triple agonism would be qualitatively different from stacking single agonists, not merely quantitatively larger.
Distinguishing between these requires data the field does not yet have. It is one of the more consequential unresolved questions in metabolic peptide research, because the answer determines whether adding a fourth receptor would help or whether the class has reached a natural ceiling.
Practical Research Notes
Retatrutide uses the same structural strategy as semaglutide and tirzepatide — a fatty-acid tail that binds reversibly to serum albumin, extending the half-life into the multi-day range. Its reported half-life of roughly six days supports the once-weekly administration used in published protocols.
Practically, this means handling is unremarkable for anyone already working with GLP-class peptides. It ships lyophilized, is reconstituted with bacteriostatic water, and is refrigerated after reconstitution. Our reconstitution guide covers the concentration math, the dosage chart converts a finished stock into U-100 syringe units, and the peptide reconstitution calculator handles any combination directly.
Helix North supplies Retatrutide 10 mg and Retatrutide 20 mg as research materials with batch-specific HPLC purity verification. Our buy retatrutide in Canada guide covers vial sizes, testing, and domestic shipping.
For Research Use Only
Everything above describes laboratory and clinical-trial research on an investigational compound. Helix North supplies retatrutide for research applications only — not for human or animal consumption, and nothing here constitutes medical, dosing, or clinical guidance.
